---
document_datetime: 2025-11-24 09:14:39
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ebvallo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ebvallo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.954827
conversion_datetime: 2025-12-14 14:03:25.114645
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Ebvallo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000306999 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted | 18/11/2025                          |                                             | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000308440   | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                   | 28/10/2025   | N/A   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000290529   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted | 26/08/2025   | N/A   |
| Variation type II / EMA/VR/0000267364   | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                                                                                             | 24/07/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000279202   | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/06/2025   | N/A   |                   |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|
| Variation type IA_IN /                  | This was an application for a group of variations. B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) | 19/06/2025   | N/A   | EMA/VR/0000280089 |

<div style=\"page-break-after: always\"></div>

| Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure)                                                                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or |

<div style=\"page-break-after: always\"></div>

| Annual reassessment - H / EMA/S/0000249324   | - Annual Reassessment - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 19/06/2025   | N/A   |                |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------|
| Variation type IB / EMA/VR/0000273511        | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z - To more accurately describe the appearance of active substance, starting material, intermediate or | 16/06/2025   | N/A   |                |
| Variation type IB / EMA/VR/0000267274        | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/05/2025   | N/A   |                |
| Variation type II / EMA/VR/0000245074        | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/05/2025   | N/A   | Not applicable |

<div style=\"page-break-after: always\"></div>

|                                       | batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                       |            |     |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                   | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted                                   | 16/05/2025 | N/A | EMA/VR/0000265257 |
| Variation type IA / EMA/VR/0000261292 | B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted | 25/03/2025 | N/A |                   |
| Variation type IB / EMA/VR/0000245895 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted   | 20/02/2025 | N/A |                   |
| Variation type IB /                   | B.I.d) Stability - B.I.d.z Other variation - Accepted                                                                                                                                                                            | 17/02/2025 | N/A | EMA/VR/0000244893 |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000257898   | Periodic Safety Update EU Single assessment - tabelecleucel   | 16/01/2025   | n/a   | PRAC Recommendation - maintenance   |
|------------------------------|---------------------------------------------------------------|--------------|-------|-------------------------------------|